Veracyte highlights Decipher Bladder data on chemo-immunotherapy response at AUA 2026

• Veracyte flagged more than 15 studies on its Decipher Bladder and Decipher Prostate tests scheduled for presentation at American Urological Association Annual Meeting on May 15-18, 2026 in Washington.
• Upcoming bladder cancer presentations indicate molecular subtyping with Decipher Bladder may help identify patients more likely to respond to neoadjuvant chemo-immunotherapy, supporting more targeted treatment selection.
• Future prostate cancer analyses using Decipher Prostate data linked with national real-world datasets suggest genomic risk information influences initial therapy choices, reinforcing clinical utility in day-to-day decision-making.
• Additional studies drawing on Decipher GRID registry data are expected to extend evidence generation in urologic cancers, supporting broader adoption and payer discussions tied to outcomes-focused use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260428470902) on April 28, 2026, and is solely responsible for the information contained therein.